{"id":"https://openalex.org/W2343833232","doi":"https://doi.org/10.1016/j.parkreldis.2015.10.194","title":"Impact of current antipsychotic medications on comparative mortality and adverse events in people with Parkinson\u2019s disease psychosis (PDP)","display_name":"Impact of current antipsychotic medications on comparative mortality and adverse events in people with Parkinson\u2019s disease psychosis (PDP)","publication_year":2015,"publication_date":"2015-12-17","ids":{"openalex":"https://openalex.org/W2343833232","doi":"https://doi.org/10.1016/j.parkreldis.2015.10.194","mag":"2343833232"},"language":"en","primary_location":{"id":"doi:10.1016/j.parkreldis.2015.10.194","doi":"https://doi.org/10.1016/j.parkreldis.2015.10.194","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.parkreldis.2015.10.194","pdf_url":null,"source":{"id":"https://openalex.org/S147691530","display_name":"Parkinsonism & Related Disorders","issn_l":"1353-8020","issn":["1353-8020","1873-5126"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Parkinsonism & Related Disorders","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5003930471","display_name":"Roger Mills","orcid":"https://orcid.org/0000-0002-3993-4180","observed_orcids":["https://orcid.org/0000-0002-3993-4180"]},"institutions":[{"id":"https://openalex.org/I125377440","display_name":"Acadia Pharmaceuticals (United States)","ror":"https://ror.org/030bhbq32","country_code":"US","type":"company","lineage":["https://openalex.org/I125377440"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Roger Mills","raw_affiliation_strings":["Acadia Pharmaceuticals, San Diego, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Acadia Pharmaceuticals, San Diego, United States","institution_ids":["https://openalex.org/I125377440"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032708452","display_name":"Clive G. Ballard","orcid":"https://orcid.org/0000-0003-0022-5632","observed_orcids":["https://orcid.org/0000-0003-0022-5632"]},"institutions":[{"id":"https://openalex.org/I183935753","display_name":"King's College London","ror":"https://ror.org/0220mzb33","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I183935753"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Clive Ballard","raw_affiliation_strings":["Wolfson Centre for Age-Related Diseases, King\u2019s College, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Wolfson Centre for Age-Related Diseases, King\u2019s College, London, United Kingdom","institution_ids":["https://openalex.org/I183935753"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060664922","display_name":"Stuart Isaacson","orcid":"https://orcid.org/0000-0002-9914-5706","observed_orcids":["https://orcid.org/0000-0002-9914-5706"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Stuart Isaacson","raw_affiliation_strings":["Parkinson's Disease and Movement Disorders Center of Boca Raton and FIU Herbert Wertheim College of Medicine, Boca Raton, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Parkinson's Disease and Movement Disorders Center of Boca Raton and FIU Herbert Wertheim College of Medicine, Boca Raton, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104349049","display_name":"Hilde Williams","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I125377440","display_name":"Acadia Pharmaceuticals (United States)","ror":"https://ror.org/030bhbq32","country_code":"US","type":"company","lineage":["https://openalex.org/I125377440"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hilde Williams","raw_affiliation_strings":["ACADIA Pharmaceuticals, San Diego, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ACADIA Pharmaceuticals, San Diego, United States","institution_ids":["https://openalex.org/I125377440"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089176981","display_name":"Anne Corbett","orcid":"https://orcid.org/0000-0003-2015-0316","observed_orcids":["https://orcid.org/0000-0003-2015-0316"]},"institutions":[{"id":"https://openalex.org/I183935753","display_name":"King's College London","ror":"https://ror.org/0220mzb33","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I183935753"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Anne Corbett","raw_affiliation_strings":["Wolfson Centre for Age-Related Diseases, King\u2019s College, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Wolfson Centre for Age-Related Diseases, King\u2019s College, London, United Kingdom","institution_ids":["https://openalex.org/I183935753"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067365646","display_name":"Bruce Coate","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I125377440","display_name":"Acadia Pharmaceuticals (United States)","ror":"https://ror.org/030bhbq32","country_code":"US","type":"company","lineage":["https://openalex.org/I125377440"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bruce Coate","raw_affiliation_strings":["ACADIA Pharmaceuticals, San Diego, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ACADIA Pharmaceuticals, San Diego, United States","institution_ids":["https://openalex.org/I125377440"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009117789","display_name":"Rajesh Pahwa","orcid":"https://orcid.org/0000-0003-3176-6466","observed_orcids":["https://orcid.org/0000-0003-3176-6466"]},"institutions":[{"id":"https://openalex.org/I4210128618","display_name":"University of Kansas Medical Center","ror":"https://ror.org/036c9yv20","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210128618"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rajesh Pahwa","raw_affiliation_strings":["Department of Neurology, Parkinson's Disease and Movement Disorder Center, University of Kansas Medical Center, Kansas City, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Neurology, Parkinson's Disease and Movement Disorder Center, University of Kansas Medical Center, Kansas City, United States","institution_ids":["https://openalex.org/I4210128618"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054027214","display_name":"Olivier Rascol","orcid":"https://orcid.org/0000-0002-1410-6397","observed_orcids":["https://orcid.org/0000-0002-1410-6397"]},"institutions":[{"id":"https://openalex.org/I134560555","display_name":"Universit\u00e9 Toulouse III - Paul Sabatier","ror":"https://ror.org/02v6kpv12","country_code":"FR","type":"education","lineage":["https://openalex.org/I134560555","https://openalex.org/I4405258862"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Olivier Rascol","raw_affiliation_strings":["Departments of Clinical Pharmacology and Neurosciences, University UPS of Toulouse III, Toulouse, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Clinical Pharmacology and Neurosciences, University UPS of Toulouse III, Toulouse, France","institution_ids":["https://openalex.org/I134560555"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5010057774","display_name":"David John Burn","orcid":"https://orcid.org/0000-0001-7658-1209","observed_orcids":["https://orcid.org/0000-0001-7658-1209"]},"institutions":[{"id":"https://openalex.org/I84884186","display_name":"Newcastle University","ror":"https://ror.org/01kj2bm70","country_code":"GB","type":"education","lineage":["https://openalex.org/I84884186"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"David Burn","raw_affiliation_strings":["Clinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne, United Kingdom","institution_ids":["https://openalex.org/I84884186"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":5,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3460,"currency":"USD","value_usd":3460},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.22221186,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"22","issue":null,"first_page":"e91","last_page":"e92"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.9413999915122986,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.9413999915122986,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.0471000000834465,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13397","display_name":"Hallucinations in medical conditions","score":0.0035000001080334187,"subfield":{"id":"https://openalex.org/subfields/2805","display_name":"Cognitive Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/parkinson-s-disease-psychosis","display_name":"Parkinson's disease psychosis","score":0.9980000257492065},{"id":"https://openalex.org/keywords/antipsychotic-drugs","display_name":"antipsychotic drugs","score":0.8429999947547913}],"concepts":[{"id":"https://openalex.org/C2779727114","wikidata":"https://www.wikidata.org/wiki/Q170082","display_name":"Psychosis","level":2,"score":0.744839608669281},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6705459356307983},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.6073154807090759},{"id":"https://openalex.org/C2780494398","wikidata":"https://www.wikidata.org/wiki/Q208144","display_name":"Antipsychotic","level":3,"score":0.5995442271232605},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5976569652557373},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.5905806422233582},{"id":"https://openalex.org/C2776921671","wikidata":"https://www.wikidata.org/wiki/Q758295","display_name":"Atypical antipsychotic","level":4,"score":0.44004130363464355},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.4234920144081116},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.372437447309494},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.3706095218658447},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.12062379717826843}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.parkreldis.2015.10.194","doi":"https://doi.org/10.1016/j.parkreldis.2015.10.194","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.parkreldis.2015.10.194","pdf_url":null,"source":{"id":"https://openalex.org/S147691530","display_name":"Parkinsonism & Related Disorders","issn_l":"1353-8020","issn":["1353-8020","1873-5126"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Parkinsonism & Related Disorders","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":21,"referenced_works":["https://openalex.org/W28928478","https://openalex.org/W1982165592","https://openalex.org/W1982860872","https://openalex.org/W1995891758","https://openalex.org/W2008490243","https://openalex.org/W2047670437","https://openalex.org/W2060220011","https://openalex.org/W2060408394","https://openalex.org/W2062784668","https://openalex.org/W2064006284","https://openalex.org/W2072511042","https://openalex.org/W2075960947","https://openalex.org/W2090929494","https://openalex.org/W2094407307","https://openalex.org/W2097646077","https://openalex.org/W2107881620","https://openalex.org/W2109069020","https://openalex.org/W2122085123","https://openalex.org/W2122683614","https://openalex.org/W2157331971","https://openalex.org/W2327877878"],"related_works":["https://openalex.org/W2144270502","https://openalex.org/W2490666500","https://openalex.org/W4396668896","https://openalex.org/W3004973163","https://openalex.org/W4409285163","https://openalex.org/W2341929952","https://openalex.org/W4250491122","https://openalex.org/W4282958777","https://openalex.org/W4318249996","https://openalex.org/W2607035188"],"abstract_inverted_index":null,"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}